Previous 10 | Next 10 |
ATLANTA, GA - ( NewMediaWire ) - October 05, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance f...
Company to Provide Updates on Phase 2 Clinical Trials for Next Generation COVID-19 Vaccine and Cancer Immunotherapy Programs ATLANTA, GA - ( NewMediaWire ) - September 27, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company develop...
ATLANTA, GA and BERLIN, Germany - ( NewMediaWire ) - September 26, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, and ProBioGen announce the signing of a landmark commercial license agreement...
ATLANTA, GA and BERLIN, Germany, Sept. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, and ProBioGen announce the signing of a landmark commercial ...
JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8 th Annual Dawson James Small Cap Growth Conferen...
Preclinical Data for GEO-CM02 Demonstrates Single-Dose Protection Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines ag...
Data Published From Phase 2 Open-Label Study of GEO-CM04S1 ATLANTA, GA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced ...
Updates Presented for Gedeptin® and GEO-CM04S1 Phase 2 Clinical Trials ATLANTA, GA - ( NewMediaWire ) - September 12, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious disea...
Multi-antigen Vaccine Designed to Protect Against Evolving SARS-CoV-2 Variants ATLANTA, GA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious disea...
Company to Provide Updates on Multiple Phase 2 Clinical Trials for GEO-CM04S1 and Gedeptin® ATLANTA, GA - ( NewMediaWire ) - August 31, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against c...
News, Short Squeeze, Breakout and More Instantly...
ATLANTA, GA - ( NewMediaWire ) - July 11, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a cert...
GeoVax Labs, Inc. (NASDAQ: GOVX) is one of today's top gainers. The company's shares have moved 20.05% on the day to $3.02. GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ank...
Award of BARDA Project NextGen contract represents a significant milestone event; total value of award to GeoVax and its CRO partner total approximately $367-388 million BARDA-funded 10,000-participant Phase 2b study will evaluate and compare GeoVax’s ...